Evolent Health, Inc. (NYSE:EVH – Get Free Report) CFO John Paul Johnson sold 44,693 shares of the firm’s stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $30.00, for a total value of $1,340,790.00. Following the sale, the chief financial officer now owns 171,207 shares of the company’s stock, valued at $5,136,210. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Evolent Health Trading Down 4.1 %
NYSE EVH traded down $1.35 on Monday, reaching $31.62. The company had a trading volume of 3,049,630 shares, compared to its average volume of 1,632,854. The stock’s 50 day moving average is $22.48 and its 200-day moving average is $26.55. The stock has a market cap of $3.67 billion, a price-to-earnings ratio of -25.30 and a beta of 1.54. The company has a quick ratio of 1.02, a current ratio of 1.02 and a debt-to-equity ratio of 0.57. Evolent Health, Inc. has a 52 week low of $17.98 and a 52 week high of $35.00.
Evolent Health (NYSE:EVH – Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The technology company reported $0.30 EPS for the quarter, beating analysts’ consensus estimates of $0.21 by $0.09. The business had revenue of $647.10 million during the quarter, compared to the consensus estimate of $636.46 million. Evolent Health had a positive return on equity of 6.90% and a negative net margin of 5.07%. The firm’s revenue was up 37.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.06 earnings per share. Equities analysts predict that Evolent Health, Inc. will post 0.9 earnings per share for the current year.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
A number of equities research analysts have commented on the company. Canaccord Genuity Group decreased their price objective on Evolent Health from $44.00 to $41.00 and set a “buy” rating for the company in a research report on Friday, May 10th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $42.00 price target on shares of Evolent Health in a research note on Monday. Truist Financial raised Evolent Health from a “hold” rating to a “buy” rating and raised their price target for the stock from $28.00 to $33.00 in a research note on Friday, August 9th. Stephens reaffirmed an “overweight” rating and set a $42.00 price target on shares of Evolent Health in a research note on Tuesday, July 30th. Finally, JPMorgan Chase & Co. raised their price objective on Evolent Health from $36.00 to $45.00 and gave the company an “overweight” rating in a research note on Monday, August 19th. One analyst has rated the stock with a sell rating and twelve have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $40.40.
View Our Latest Report on Evolent Health
About Evolent Health
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.
See Also
- Five stocks we like better than Evolent Health
- ETF Screener: Uses and Step-by-Step Guide
- Why the Buy-and-Hold Strategy May Be Best for Most Investors
- Find and Profitably Trade Stocks at 52-Week Lows
- Eli Lilly’s Path to the Next Trillion Market Capitalization
- Why is the Ex-Dividend Date Significant to Investors?
- Mobileye Global: CEO Makes $10 Million Bet on Future Strength
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.